STONY BROOK, N.Y., Jan. 29 /PRNewswire-FirstCall/ -- Applied DNA
Sciences, Inc. (OTC Bulletin Board: APDN), a DNA security solutions
company, today announced that Dr. James A. Hayward, Chief Executive
Officer, will deliver a presentation at the Anti-Counterfeiting for
Pharmaceuticals Conference to be held January 30-31 in Philadelphia, PA.
The counterfeiting of pharmaceuticals is a large and growing problem
throughout the world. It has been estimated that the pharmaceutical
industry loses $32 billion to counterfeiting globally each year (U.S.
Chamber of Commerce). A study by Columbia University's National Center on
Addiction and Substance Abuse documented that only 11% of internet
pharmacies are legitimate. In 2006, the Center for Medicine in the Public
Interest predicted that counterfeit drug sales would increase more than 90%
from 2005 levels to reach $75 billion globally by 2010, nearly twice the
growth rate of legitimate pharmaceuticals. According to the World Health
Organization, over 10% of the global medicine market is estimated to be
counterfeit, posing a health threat to patients everywhere.
Dr. Hayward's talk, entitled "The Power of DNA in Detecting and
Defeating Pharmaceutical Counterfeiting," will address this disturbing
trend and present the use of DNA embedment to combat counterfeiting in
pharmaceuticals. DNA embedment offers a broadly applicable, convenient and
inexpensive way to help protect pharmaceuticals from counterfeiting. APDN's
platform for DNA embedment, uses unique DNA "chimers," is derived from
botanical sources, and is marketed as the "SigNature" brand. The SigNature
DNA Markers are highly resistant to reverse engineering or replication, and
can either be applied independently or to supplement other security
taggants in order to allow for a forensic level of authentication. APDN's
SigNature DNA Markers can easily be embedded directly into pharmaceutical
packaging, combined with RFID (radio frequency identification) tags,
holograms, or EPC's (electronic product codes). APDN has demonstrated that
our SigNature DNA markers may be applied directly onto single unit doses of
drugs such as pressed tablets, and thereby ensure drug authenticity
regardless of packaging.
"This is a rapidly growing problem which threatens the health and
safety of people everywhere." Dr. Hayward stated. "APDN's SigNature Program
can quickly and reliably authenticate and identify counterfeit versions of
pharmaceuticals, diminishing product diversion and enabling companies to
detect, deter, interdict and prosecute counterfeiting enterprises and
individuals. I welcome this opportunity to introduce the potential power of
our DNA technology as both a way to deter counterfeiting and help protect
About Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc. (APDN) provides botanical DNA encryption,
embedment and authentication solutions that can help protect companies,
governments and consumers from counterfeiting, fraud, piracy, product
diversion, identity theft and unauthorized intrusion into physical
locations and databases. Our common stock is registered under Section 12(g)
of the Securities Exchange Act of 1934 and is listed on the
Over-The-Counter Bulletin Board under the symbol "APDN". Contact: Debbie
Bailey, Applied DNA Sciences, Inc., 25 Health Sciences Drive, Stony Brook,
New York 11790; Tel: 631-444- 8090; Fax: 631-444-8848 http://www.ADNAS.com.
The statements made by Applied DNA Sciences, Inc. may be
forward-looking in nature and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements describe the Company's future plans,
projections, strategies and expectations, and are based on assumptions and
involve a number of risks and uncertainties, many of which are beyond the
control of Applied DNA Sciences, Inc. Actual results could differ
materially from those projected due to our short operating history, limited
market acceptance, market competition and various other factors detailed
from time to time in Applied DNA Sciences' SEC reports and filings,
including our Registration Statement on Form SB-2 as amended, and our
Annual Report on Form 10-KSB, filed on January 16, 2007. The Company
undertakes no obligation to update publicly any forward-looking statements
to reflect new information, events or circumstances after the date hereof
to reflect the occurrence of unanticipated events.
SOURCE Applied DNA Sciences, Inc.